ArticleInternational journal of clinical and experimental pathology2018
Mesenchymal stem cells were affected by up-regulation of miRNA-21 in vitro.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- MicroRNA Regulation of Bone Marrow Mesenchymal Stem Cell Chondrogenesis: Toward Articular Cartilage.Tissue engineering. Part A · 2022Article
- MiRNA-21 promotes differentiation of bone marrow mesenchymal stem cells into cardiomyocyte-like cells by regulating the Ajuba/Isl1 axis pathway.Archives of medical science : AMS · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe expression of miRNA-21 was high in cells that were derived from MSCs, but, the role of miRNA-21in the MSCs was unknown. MATERIAL/
methodsIn this study, flow cytometry, which was used to identify the surface-associated antigens of MSCs. The 10 μmol/l 5-azacytidine was used to induce MSCs to differentiate to cardiomyocyte-like cells. Immunofluorescence, that was for detected the expression of troponin I (cTnI). The samples were assigned to 3 groups: the blank group, the miRNA-21 mimic group, and the negative control (NC) group. The proliferation of MSCs was detected by methyl thiazolylte-trazolium (MTT), the apoptosis of MSCs was analyzed by flow cytometry, Western-blot, which was used to identify the expression of cTNI and myoD in the MSCs.
resultsThe proliferation of MSCs was increased, because of the over expression of miRNA-21; But, the apoptotic rate of the MSCs were slower in MIRNA-21 group, on account of the expression of miRNA-21 was higher than that of in the NC and CK groups. The expression of cTNI in miRNA-21 group was higher than that of in the NC and CK groups.
conclusionsThe results also suggested that, the up-regulation of miRNA-21 enhanced proliferation of MSCs, reducing the apoptosis of MSCs. MiRNA-21 promotes the differentiation of MSCs, which may pave the way for the treatment directed toward restoring miRNA-21 function for myocardial ischemia.
Indexed as
Identifiers
31938084PMC6957933W3011923887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.